- Trial phase
- Approved
- Time to market
- Already approved and commercialized since October 2021.
- Why 4/10
- Tyrvaya is already FDA-approved and commercialized with no pending regulatory decision; the defining binary (FDA approval in October 2021) passed years ago. For Viatris, the drug was divested in October 2026 and is no longer a material part of the thesis. For Harrow, the next catalyst is commercial execution (sales ramp), which is not a hard binary catalyst. Impact score is 4 per the rubric for an approved drug with no pending regulatory decision.
Tyrvaya is now owned by Harrow (HROW), not Viatris (VTRS). The next catalyst is Harrow's commercial execution: Tyrvaya closed on October 5, 2026, so its contribution to Harrow's Q4 2026 and full-year 2027 results will be the key metric to watch. Harrow expects Tyrvaya to add more than $30M in 2027 revenue. For Viatris, Tyrvaya is a divested non-core asset with no further impact.
Price Chart
Executive Summary
Tyrvaya (varenicline solution) is an FDA-approved nasal spray for dry eye disease, first approved in October 2021 as the first and only nasal spray for this indication. Originally developed by Oyster Point Pharma, it was acquired by Viatris (VTRS) in early 2023 as part of a broader ophthalmology push. However, Viatris sold the global rights to Harrow (HROW) in August 2026 for up to $100M, with the deal closing on October 5, 2026. For Viatris, Tyrvaya is now a divested non-core asset. For Harrow, Tyrvaya is a differentiated product expected to contribute more than $30M in 2027 revenue, complementing its existing ophthalmic portfolio. The drug faces competition from established dry-eye drops but offers a novel nasal-spray delivery mechanism that stimulates natural tear production.
How It Works
Tyrvaya is a nasal spray that delivers varenicline, a chemical that activates certain nerve receptors (nicotinic acetylcholine receptors) in the nose. This stimulation triggers the trigeminal parasympathetic pathway, a natural nerve circuit that signals the tear glands to produce more of the eye's own basal tears. Unlike eye drops that add artificial moisture, Tyrvaya aims to boost the body's natural tear production.
Trial Status
FDA-approved in October 2021 based on the ONSET-1 and ONSET-2 Phase 3 clinical trials, which showed statistically significant increases in tear production (Schirmer's score) at 4 weeks. The drug has been commercially available in the U.S. since November 2021 and is also approved in China and other markets.
The Two-Sided Case
Upcoming Catalysts
- Harrow Q4 2026 earnings (early 2027) - first full quarter of Tyrvaya ownership
- Harrow full-year 2027 revenue guidance - Tyrvaya expected to contribute >$30M
- Potential geographic expansion milestones in ex-U.S. markets
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Viatris Inc 8-K VTRS ·Originating report